Form 4: Applied Therapeutics' Chief Commercial Officer Receives 300,000 Restricted Stock Units

Corwin Dale Hooks, Chief Commercial Officer of Applied Therapeutics, Inc., was granted 300,000 compensatory Restricted Stock Units on April 12, 2024, under the company's 2019 Equity Incentive Plan.

Summary

• On April 12, 2024, Corwin Dale Hooks, the Chief Commercial Officer of Applied Therapeutics, Inc., received 300,000 compensatory Restricted Stock Units (RSUs).
• These RSUs were granted under the company's 2019 Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of Applied Therapeutics' common stock.
• The vesting schedule for these RSUs is as follows: one-fourth (1/4th) will vest on April 12, 2025, and one thirty-sixth (1/36th) of the remaining shares will vest each month thereafter.
• Vesting is contingent upon the reporting person continuing to provide services through each vesting date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of RSUs is a standard practice and indicates confidence in the executive's continued contributions. There are no explicitly negative aspects mentioned.

Positives

• The grant of RSUs aligns the executive's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.

Risks

• The vesting of the RSUs is contingent upon continued service, so any departure of the executive would result in forfeiture of unvested units.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance, but the equity grant suggests an expectation of continued contributions from the executive.

Industry Context

Equity compensation is a common practice in the pharmaceutical industry to attract and retain key talent, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• The size and vesting schedule of the grant would need to be compared to similar companies and executive roles to determine if it is in line with industry norms.
• Companies like BioMarin, Vertex, and Sarepta Therapeutics also utilize equity-based compensation for their executives.

Stakeholder Impact

• Shareholders may view the equity grant positively as it incentivizes the executive to work towards increasing shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates